We provide you with 20 years of free, institutional-grade data for HRMY stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of HRMY. Explore the full financial landscape of HRMY stock.
Total insider purchase within 3 month on this page: $0
Total insider selling within 3 month on this page: -$787,377
| Name | Action | Shares | Avg Price | Amount | Reported Date |
|---|---|---|---|---|---|
| Kapadia Sandip | Sale | -21,573 | $36.5 | $787,378 | 2025-08-19 |
| Budur Kumar | Sale | -8,869 | $29.86 | $264,828 | 2025-05-09 |
| Budur Kumar | Derivatives Exercise | 18,750 | 2025-05-09 | ||
| Kapadia Sandip | Sale | -6,987 | $32.48 | $226,913 | 2025-04-03 |
| Kapadia Sandip | Sale | -8,014 | $33.19 | $265,985 | 2025-04-01 |
| Kapadia Sandip | Derivatives Exercise | 15,000 | 2025-04-01 | ||
| Dierks Jeffrey | Sale | -4,869 | $32.61 | $158,780 | 2025-03-05 |
| Dierks Jeffrey | Derivatives Exercise | 4,869 | 2025-03-05 | ||
| Kapadia Sandip | Sale | -3,812 | $38.01 | $144,894 | 2025-01-28 |
| Kapadia Sandip | Derivatives Exercise | 3,812 | 2025-01-28 | ||
| Serafin Andrew | Sale | -865 | $38.01 | $32,879 | 2025-01-28 |
| Serafin Andrew | Derivatives Exercise | 2,500 | 2025-01-28 | ||
| Dayno Jeffrey M. | Sale | -4,567 | $38.01 | $173,592 | 2025-01-28 |
| Dayno Jeffrey M. | Derivatives Exercise | 10,500 | 2025-01-28 | ||
| Budur Kumar | Sale | -1,151 | $38.01 | $43,750 | 2025-01-28 |
| Budur Kumar | Derivatives Exercise | 2,187 | 2025-01-28 | ||
| Dierks Jeffrey | Sale | -15,812 | $36.94 | $584,117 | 2025-01-28 |
| Dierks Jeffrey | Derivatives Exercise | 15,812 | 2025-01-28 | ||
| Kapadia Sandip | Sale | -25,000 | $40.18 | $1,004,598 | 2025-01-23 |
| Kapadia Sandip | Derivatives Exercise | 25,000 | 2025-01-23 | ||
| Dayno Jeffrey M. | Sale | -19,293 | $40.13 | $774,245 | 2025-01-23 |
| Dayno Jeffrey M. | Derivatives Exercise | 19,293 | 2025-01-23 | ||
| Dierks Jeffrey | Sale | -30,598 | $37.41 | $1,144,812 | 2025-01-21 |
| Dierks Jeffrey | Derivatives Exercise | 30,598 | 2025-01-21 | ||
| Dierks Jeffrey | Sale | -10,507 | $37.01 | $388,841 | 2025-01-16 |
| Dierks Jeffrey | Derivatives Exercise | 10,507 | 2025-01-16 | ||
| Dierks Jeffrey | Sale | -7,180 | $37.04 | $265,946 | 2025-01-15 |
| Dierks Jeffrey | Derivatives Exercise | 7,180 | 2025-01-15 | ||
| Marshman Fund Trust II | Sale | -4,600,000 | $30.3 | $139,391,500 | 2024-11-05 |
| Valor IV Pharma Holdings, LLC | Sale | -4,600,000 | $30.3 | $139,391,500 | 2024-11-05 |
| Dierks Jeffrey | Sale | -21,496 | $40.47 | $870,018 | 2024-10-31 |
| Dierks Jeffrey | Derivatives Exercise | 21,496 | 2024-10-31 | ||
| Dierks Jeffrey | Sale | -36,357 | $35.05 | $1,274,142 | 2024-10-07 |
| Kapadia Sandip | Sale | -32,052 | $40 | $1,282,080 | 2024-10-02 |
| Kapadia Sandip | Derivatives Exercise | 60,000 | 2024-10-02 | ||
| Dierks Jeffrey | Sale | -24,043 | $40.19 | $966,343 | 2024-10-02 |
| Dierks Jeffrey | Derivatives Exercise | 60,400 | 2024-10-02 | ||
| Dierks Jeffrey | Sale | -35,846 | $40.03 | $1,434,951 | 2024-10-01 |
| Dierks Jeffrey | Derivatives Exercise | 35,846 | 2024-10-01 | ||
| Dierks Jeffrey | Sale | -200 | $40.05 | $8,009 | 2024-09-30 |
| Dierks Jeffrey | Derivatives Exercise | 200 | 2024-09-30 | ||
| Kapadia Sandip | Sale | -8,013 | $33.58 | $269,077 | 2024-04-02 |
| Kapadia Sandip | Derivatives Exercise | 15,000 | 2024-04-02 | ||
| Dierks Jeffrey | Sale | -11,979 | $32 | $383,328 | 2024-03-18 |
| Dierks Jeffrey | Derivatives Exercise | 11,979 | 2024-03-18 | ||
| Dierks Jeffrey | Sale | -194 | $32 | $6,208 | 2024-03-11 |
| Dierks Jeffrey | Derivatives Exercise | 194 | 2024-03-11 | ||
| Budur Kumar | Initial | 2024-01-26 | |||
| Kapadia Sandip | Sale | -15,414 | $33.36 | $514,211 | 2023-03-31 |
| Kapadia Sandip | Derivatives Exercise | 30,000 | 2023-03-31 | ||
| Nielsen Jack | Sale | -2,834 | $59.96 | $169,927 | 2022-12-16 |
| Wicki Andreas | Sale | -28,841 | $60.36 | $1,740,843 | 2022-12-14 |
| Nielsen Jack | Sale | -110,751 | $60.35 | $6,683,823 | 2022-12-09 |
| Wicki Andreas | Sale | -77,853 | $61.23 | $4,766,939 | 2022-12-07 |
| Serafin Andrew | Sale | -38,000 | $60.12 | $2,284,556 | 2022-12-05 |
| Serafin Andrew | Derivatives Exercise | 38,000 | 2022-12-05 | ||
| Nielsen Jack | Sale | -129,652 | $57.82 | $7,496,479 | 2022-12-01 |
| Nielsen Jack | Sale | -77,600 | $57 | $4,423,200 | 2022-11-22 |
| Wicki Andreas | Sale | -51,278 | $59.1 | $3,030,530 | 2022-11-16 |
| Nielsen Jack | Sale | -158,400 | $57.14 | $9,050,976 | 2022-11-15 |
The information provided in this report about HRMY stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Harmony Biosciences Holdings, Inc(NASDAQ:HRMY) 
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy in the United Sta...
Website: https://www.harmonybiosciences.com/
Founded: 2017
Full Time Employees: 150
CEO: John C.s Jacobs
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends